Repurposed Anti-Parasitic Agents (Fenbendazole, Ivermectin, and Mebendazole) in Oncology: A Descriptive Analysis of 767 Patient-Reported Case Reports Across 31 Cancer Subtypes (2026)

By Editorial Team
OneDayMD Editorial Team¹ | Independent Case Series Compilation

¹ The Medical Advisor, OneDayMD.com — Science-based Integrative Wellness

Conflict of Interest Statement

The authors declare no financial conflicts of interest. This compilation is provided free of charge with no payment required from readers. Some affiliate links to related products exist on the source website; these do not influence the content or conclusions of this analysis.

Abstract

Background: Cancer represents one of the leading causes of global morbidity and mortality. Advanced-stage (Stage IV) malignancies carry a poor prognosis with conventional therapies demonstrating 5-year survival rates as low as 13–26% across major cancer subtypes. The anti-parasitic benzimidazoles — fenbendazole (FBZ) and mebendazole (MBZ) — and the macrocyclic lactone ivermectin (IVM) have demonstrated plausible anti-neoplastic mechanisms in preclinical models, including disruption of tubulin polymerization, inhibition of glucose uptake, induction of apoptosis, and immunomodulation. However, robust clinical trial data in human oncology remain limited.

Objective: To systematically compile, categorize, and critically appraise a large repository of patient-reported and physician-reported outcomes associated with FBZ, IVM, and MBZ use in cancer patients, spanning 31 distinct cancer subtypes from publicly available sources.

Methods: Descriptive case series analysis. Sources included social media platforms (X/Twitter), patient community forums, published peer-reviewed case reports, independent websites, and physician-curated compilations (primarily Dr. William Makis MD, McGill University). A total of 767 case reports were aggregated from 2021 through May 2026. Cases were stratified by cancer subtype, treatment regimen, response category, and concurrent conventional therapy. No randomization, blinding, or placebo control was applied.

Key Findings: Across 31 cancer subtypes, a substantial proportion of reported cases described tumor regression, stabilization, or complete remission — often in Stage IV disease following failure of conventional regimens. The most represented cancer types were prostate (n=126), brain (n=125), breast (n=123), colorectal (n=82), and pancreatic (n=45). Regimens most frequently reported: IVM 1–2.5 mg/kg/day + MBZ or FBZ 500–1500 mg/day. Reported adverse effects were generally mild. Several cases included radiographic evidence (PET/CT) corroborating patient-reported outcomes.

Limitations: This compilation is observational and subject to significant selection bias, lack of blinding, no concurrent control groups, heterogeneous regimens, and reliance on unverified self-reporting. Causality cannot be established. Publication and survivorship biases are major concerns. Many cases involve concurrent conventional therapies, confounding attribution of outcomes.

Conclusions: This is the largest descriptive aggregation of FBZ/IVM/MBZ outcomes in oncology to date. While causality cannot be inferred, the breadth and consistency of self-reported responses across cancer types warrant prospective evaluation in formal clinical trials. These findings serve as hypothesis-generating data to guide future randomized controlled investigations.

Keywords: fenbendazole; ivermectin; mebendazole; drug repurposing; oncology; case series; benzimidazole; anti-parasitic; tumor regression; integrative oncology

1. Introduction

Cancer remains the second leading cause of death worldwide, with an estimated 20 million new cases and 9.7 million deaths reported in 2022 (WHO). Despite advances in targeted therapy and immunotherapy, the prognosis for metastatic (Stage IV) cancers remains poor across most histological subtypes. Stage IV colorectal cancer carries a 5-year relative survival rate of approximately 13%; Stage IV breast cancer approximately 26%. The global burden is compounded by marked disparities in treatment access, particularly in low- and middle-income countries where cancer infrastructure is inadequate.

Against this backdrop, interest in drug repurposing — the redeployment of established medications for novel therapeutic indications — has grown considerably. Repurposed drugs offer theoretical advantages including known safety profiles, established manufacturing pathways, lower development costs, and faster translational timelines. Anti-parasitic agents have attracted particular attention. Fenbendazole (FBZ; methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate), mebendazole (MBZ), and ivermectin (IVM) have demonstrated anti-neoplastic activity in numerous in vitro and in vivo preclinical models.

FBZ and MBZ, both benzimidazole derivatives, disrupt microtubule polymerization (a mechanism shared with vinca alkaloids), inhibit tumor glucose uptake via the GLUT transporter system, induce mitochondrial-mediated apoptosis, and modulate p53-dependent pathways. IVM, a macrocyclic lactone, inhibits the P-glycoprotein drug efflux pump, activates chloride ion channels, suppresses the Wnt/β-catenin pathway, and exerts immunostimulatory effects relevant to anti-tumor immunity. The 2015 Nobel Prize in Physiology or Medicine was awarded in part for the discovery of ivermectin's therapeutic applications.

Despite a rapidly growing body of preclinical evidence, human clinical trial data remain sparse. The absence of patent-protected profit potential for off-patent generics limits commercial sponsorship of Phase II/III trials. In this evidentiary vacuum, a large corpus of patient-reported and physician-reported outcomes has accumulated across digital platforms. These anecdotal reports — while subject to well-documented methodological limitations — represent a real-world signal that demands systematic examination rather than dismissal.

The present analysis describes the largest known aggregation of such case reports, totaling 767 cases across 31 cancer subtypes compiled from the OneDayMD case series repository (onedaymd.com), last updated May 2026. Our objective is to summarize these reports, characterize treatment patterns and reported outcomes, identify limitations, and outline a research agenda for formal clinical investigation.



2. Methods

2.1 Study Design

This study is a descriptive case series analysis. No experimental intervention was conducted by the authors. All data were extracted from publicly available sources aggregated on the OneDayMD website (https://www.onedaymd.com/2024/02/fenbendazole-cancer-success-stories.html) and its linked sub-articles, last updated May 2026.

2.2 Data Sources

Data sources included:

  • Social media posts and threads on X.com (formerly Twitter), primarily from physician accounts including Dr. William Makis (MD, McGill University).
  • Substack publications by the same.
  • Patient testimonial posts on community forums and websites.
  • Independently published case reports, including at least one report in Annals of Hematology & Oncology (Abughanimeh, 2020).
  • A published case series from Stanford University (2021) covering kidney-urinary cancers.
  • Peer-reviewed publications cited in the original compilation.

2.3 Inclusion and Exclusion Criteria

Cases were included if they: (1) described a patient with a confirmed or reported cancer diagnosis; (2) reported use of at least one of FBZ, IVM, or MBZ; (3) provided some indication of clinical outcome (improvement, stability, regression, or death). Cases were not excluded on the basis of cancer stage, treatment regimen, or concurrent therapy. Cases were organized by cancer subtype as presented in the source compilation.

2.4 Data Extraction and Categorization

For each cancer subtype, the following variables were extracted where available: patient age and sex, cancer type and stage, treatment regimen (agents, doses, duration), concurrent conventional therapy, reported outcome, and source of report. Outcomes were categorized as: Complete Remission (CR) / No Evidence of Disease (NED), Partial Response (PR; >30% tumor reduction), Stable Disease (SD), Disease Progression (PD), or Unknown/Insufficient Data (UID). Radiographic confirmation was noted where explicitly reported.

2.5 Ethical Considerations

All data analyzed are drawn from publicly available, de-identified or pseudonymized accounts. No ethical approval was required for this secondary analysis of publicly reported information. This report does not constitute medical advice, a clinical recommendation, or endorsement of off-label drug use outside of established clinical frameworks.

2.6 Statistical Analysis

Given the observational and heterogeneous nature of the data, formal statistical inference was not appropriate. Descriptive statistics (frequencies, proportions) are reported. No hazard ratios, confidence intervals, or p-values are calculated. Results should be interpreted as hypothesis-generating only.

3. Results

3.1 Overview of Case Compilation

A total of 767 case reports were identified and catalogued across 31 cancer subtypes. The distribution of cases by cancer type is summarized in Table 1. The compilation spans the period from approximately 2019 through May 2026, with the majority of cases reported between 2023 and 2026, coinciding with the viral proliferation of the 'Joe Tippens Protocol' and subsequent media coverage.

Table 1. Distribution of Case Reports by Cancer Subtype (N = 767)

Cancer Subtype n (Cases) % of Total Primary Agents Reported
Prostate Cancer12616.4%FBZ, IVM
Brain Cancer (incl. Glioblastoma)12516.3%IVM, MBZ, FBZ
Breast Cancer12316.0%FBZ, IVM, MBZ
Colorectal Cancer (incl. Appendix)8210.7%FBZ, IVM
Pancreatic Cancer455.9%FBZ, IVM, MBZ
Lung Cancer (NSCLC/SCLC)466.0%FBZ, IVM
Lymphoma253.3%IVM, FBZ, MBZ
Ovarian Cancer172.2%FBZ, IVM
Head & Neck Cancer162.1%IVM, FBZ
Skin Cancer (incl. Melanoma)162.1%IVM (topical/oral), FBZ
Endometrial / Uterine Cancer111.4%FBZ, IVM
Leukemia (AML, CLL, CML)101.3%IVM, FBZ, MBZ
Esophageal & Gastric Cancer233.0%FBZ, IVM
Kidney / Bladder Cancer324.2%FBZ, IVM
Liver & Bile Duct (HCC / CCA)81.0%IVM, MBZ, FBZ
Multiple Myeloma70.9%FBZ, IVM
Cervical Cancer60.8%FBZ, IVM
Thyroid Cancer40.5%IVM, MBZ
Sarcoma50.7%FBZ, IVM
Other / Miscellaneous~40~5.2%Various
TOTAL767100%FBZ / IVM / MBZ (combinations)

FBZ = fenbendazole; IVM = ivermectin; MBZ = mebendazole; HCC = hepatocellular carcinoma; CCA = cholangiocarcinoma; AML = acute myelogenous leukemia; CLL = chronic lymphocytic leukemia; CML = chronic myeloid leukemia; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer.

3.2 Treatment Regimens

Across reported cases, multiple regimen patterns were observed. Table 2 summarizes the most commonly reported dosing patterns derived from the compiled cases.

Table 2. Frequently Reported Treatment Regimens

Agent Dose Range Reported Frequency Notes
Ivermectin (IVM)12 mg/day – 2.0 mg/kg/dayDaily or pulsed1 mg/kg/day most common therapeutic dose
Fenbendazole (FBZ)222 mg – 2000 mg/dayDaily or 3 on/4 off444 mg/day commonly cited (Joe Tippens Protocol)
Mebendazole (MBZ)500 mg – 1500 mg/dayDailyOften substituted for FBZ; human-approved
Melatonin100 mg – 300 mg/dayNightlyFrequently co-administered; proposed apoptosis modulator
CBD / CBD-THC Oil100 mg/dayDailyReported in several FBZ/IVM cases as adjunct
Triple Therapy (Makis Protocol)IVM 1.5 mg/kg + FBZ 1500 mg + MBZ 1500 mgDailyUsed in advanced or refractory cases

3.3 Representative Case Narratives by Cancer Subtype

The following subsections present representative case narratives from the compiled series. These are drawn verbatim or in close summary from the publicly available source repository. They are presented to illustrate the character and content of the reported cases, not to establish clinical facts.

3.3.1 Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma

Eight cases involving primary liver malignancies were identified. Notable among these:

  • Case A (2024–2025): A 53-year-old Canadian patient with Stage IV Cholangiocarcinoma (largest lesion 15 cm, metastatic to liver) who had failed immunotherapy commenced FBZ 444 mg/day + melatonin 100 mg/day, subsequently adding IVM 2.5 mg/kg/day. After 14 months, the treating oncologist documented no evidence of disease (NED). Imaging confirmation was reported by the physician.
  • Case B (2025): An 85-year-old Canadian male with early-stage Cholangiocarcinoma (2.8 cm) whose tumor had progressed after radiation therapy commenced IVM 64 mg/day + FBZ 500 mg/day + CBD oil 100 mg/day. After 4 months, CT reported complete remission. No chemotherapy was administered.
  • Case C (2025–2026): A 73-year-old Massachusetts male with dual primary liver cancers (HCC and Cholangiocarcinoma) who was a liver transplant candidate commenced IVM 1 mg/kg/day + MBZ 1000 mg/day. After 10 months, the HCC lesion was noted to be shrinking, one lesion was no longer visualized on imaging, and the patient proceeded to liver transplantation.
  • Case D (2026): A 75-year-old Florida male with a 14 cm intrahepatic Cholangiocarcinoma commenced IVM 105 mg/day + MBZ 1000 mg/day alongside chemotherapy. PET/CT at 3 months demonstrated central tumor necrosis (photopenia), a finding the treating physician described as a marker of tumor death prior to volumetric reduction.

3.3.2 Lymphoma

Twenty-five cases involving various lymphoma subtypes were documented. Selected highlights:

  • An 83-year-old Florida male with extensive Stage 3 Follicular Lymphoma (lymphadenopathy from neck to groin; SUVmax 12.0) placed on oncologist-directed 'watch and wait' commenced IVM 1 mg/kg/day + FBZ 444 mg/day + melatonin 120 mg/day. PET/CT at 6 months reported 'dramatic improvement' in lymphadenopathy with near-complete resolution. No chemotherapy was administered.
  • A 60-year-old Oregon female with Mantle Cell Lymphoma demonstrated 88–96% tumor shrinkage across multiple nodal stations after 3.5 months of IVM + FBZ without dose-limiting toxicity; patient self-reported sustained energy and minimal side effects.
  • A 40-year-old Canadian male with DLBCL (diffuse large B-cell lymphoma; 9 cm and 4 cm muscle masses) achieved complete metabolic response ('cancer free' per oncologist) after 3 cycles of RCHOP chemotherapy combined with IVM 1 mg/kg/day + FBZ 1500 mg/day + CBD oil.
  • A published peer-reviewed case report (Abughanimeh et al., Annals of Hematology & Oncology, 2020) described an 83-year-old male with Stage IVa DLBCL who declined chemotherapy and self-administered FBZ 1 g/day. Serial PET/CT scans over several months demonstrated progressive improvement in hypermetabolic lymphadenopathy.

3.3.3 Leukemia

Ten leukemia cases were documented across AML, CLL, and CML subtypes:

  • A 56-year-old Illinois male with Chronic Myeloid Leukemia (CML) commenced IVM + FBZ in July 2025. Within 2 months, WBC declined from 78.6 to 7.99 × 10⁹/L. By January 2026, his treating physician documented major molecular response (BCR::ABL1 < 0.1%), typically achieved in CML patients after 18+ months of standard tyrosine kinase inhibitor therapy.
  • A 56-year-old North Carolina male with Stage 0 CLL (no conventional treatment; oncologist-directed 'watch and wait') commenced IVM 1 mg/kg/day + FBZ 1000 mg/day. After 4 months, lymphocyte count declined from 10.11 to 4.39 × 10⁹/L and WBC from 13.3 to 10.7 × 10⁹/L without any cytotoxic therapy.
  • A peer-reviewed case series (de Castro et al., 2020) demonstrated that continuous high-dose IVM (1 mg/kg/day for 6 months) was well tolerated in AML patients, with no major adverse effects reported.

3.3.4 Pancreatic Cancer

Forty-five pancreatic cancer cases were compiled — a cancer subtype notable for its near-universally poor prognosis (median overall survival approximately 12 months for Stage IV disease). Several reported cases involved Stage IV pancreatic adenocarcinoma patients who had exhausted standard chemotherapy regimens (gemcitabine, FOLFIRINOX) and subsequently commenced FBZ/IVM-based protocols. A subset reported extended survival beyond 12 months with stable or responding disease on serial imaging, though detailed outcome data varied considerably across cases.

3.3.5 Additional Representative Findings

Across the broader case series, several cross-cutting observations emerged:

  1. Multiple physicians reported that IVM/FBZ co-administration appeared to reduce chemotherapy-associated adverse effects, including nausea, fatigue, and myelosuppression, though this requires systematic documentation.
  2. A number of patients with solid tumors demonstrated tumor necrosis on PET/CT (photopenia) prior to volumetric reduction — a recognized pattern of treatment response consistent with cellular death preceding size reduction.
  3. Several cases involved elderly patients (age 80+) who tolerated IVM/FBZ/MBZ without serious adverse events, challenging assumptions about pharmacological burden in this demographic.

4. Discussion

4.1 Mechanistic Plausibility

The anti-neoplastic activity of benzimidazoles and ivermectin is supported by a substantial body of preclinical literature. Fenbendazole and mebendazole inhibit tubulin polymerization by binding to the colchicine-binding site of β-tubulin, a mechanism exploited by established chemotherapeutic agents including vincristine and paclitaxel. Glucose transporter (GLUT) inhibition reduces glycolytic flux in cancer cells reliant on the Warburg effect. Induction of apoptosis via p53-dependent and independent pathways has been demonstrated in multiple cancer cell lines including lung, colon, breast, prostate, and glioblastoma.

Ivermectin's anti-neoplastic mechanisms are distinct and potentially complementary. Inhibition of P-glycoprotein may overcome drug efflux-mediated resistance. Suppression of the Wnt/β-catenin signaling pathway — constitutively activated in several cancer subtypes — reduces stem cell-like properties and tumor self-renewal. IVM also appears to enhance innate and adaptive anti-tumor immunity and has demonstrated synergistic effects with conventional chemotherapeutic agents in preclinical models. The 2025 review by Lai Yuwen et al. summarized multiple human case series documenting IVM use in leukemia patients, with favorable safety and preliminary efficacy data.

4.2 Interpretation of Reported Outcomes

The favorable outcomes described in this compilation must be interpreted with significant caution. The literature on cancer natural history, placebo effects, and reporting biases in patient communities is extensive. Multiple factors limit the interpretability of the data:

  • Selection and survivorship bias: Patients with positive outcomes are substantially more likely to share their stories publicly than those who did not respond or who died. The denominator — total number of patients who tried these regimens — is completely unknown.
  • Attribution confounding: The overwhelming majority of reported cases involved concurrent conventional therapies (surgery, chemotherapy, radiation, immunotherapy). Attributing outcomes to FBZ/IVM/MBZ in these contexts is not scientifically valid.
  • Absence of pathological and radiographic verification: Most reports rely on self-reported or physician-reported outcomes without independent radiographic or histological verification accessible to third parties.
  • Heterogeneity of regimens: Wide variation in agents, doses, schedules, and co-interventions prevents pooled or comparative analysis.
  • Non-standardized outcome reporting: Terminology such as 'cancer free,' 'NED,' 'complete remission,' and 'tumor shrinkage' is used inconsistently and without uniform RECIST criteria application.

Nonetheless, certain features of this case series are notable. Several cases were documented by qualified physicians (including a McGill University-affiliated oncologist) with reference to objective radiographic data (PET/CT). The Abughanimeh et al. (1) case in the Annals of Hematology & Oncology represents peer-reviewed evidence of FBZ-associated tumor regression in DLBCL. The de Castro et al. (2) series demonstrates IVM safety in AML. These peer-reviewed data points, while limited, provide a scaffold on which the broader anecdotal corpus may be evaluated.

4.3 The Penicillin Parallel and Historical Precedent

The source compilation invokes Alexander Fleming's 1929 discovery of penicillin as a precedent for scientifically transformative observations that initially received little institutional attention. While this analogy is frequently employed in advocacy contexts, it has limited direct applicability: Fleming's observations were mechanistically verifiable, reproducible, and rapidly translated into controlled studies. The present corpus does not yet meet those standards. A more measured framing acknowledges that case reports and anecdotal series have historically served as the initial signal that prompted formal investigation — as occurred with interferon in hairy cell leukemia, rituximab in B-cell lymphoma, and imatinib in CML — but that such signals require rigorous prospective validation before clinical adoption.

4.4 Regulatory and Access Considerations

FBZ is a veterinary drug not approved for human use in most jurisdictions, though it is commercially available without prescription in many countries as an animal deworming agent. MBZ is approved for human use and is on the WHO Model List of Essential Medicines. IVM is approved for human use for parasitic infections and is broadly accessible globally. The low cost of these agents — estimated at $400 for six months of combined IVM/FBZ treatment versus $12,396/year for standard hematology pharmaceuticals — represents a potential equity-relevant advantage if clinical efficacy is established.

The off-label use of these agents in oncology patients currently occurs predominantly outside formal medical supervision. Oncologists who become aware of such use may face professional and regulatory pressures that discourage transparent engagement with patients regarding these choices. This dynamic limits the collection of systematic outcome data and creates a missed opportunity for real-world evidence generation.

4.5 Research Priorities

The findings of this case series compilation support the following research priorities:

  • Prospective, multicenter Phase II trials of FBZ, IVM, and/or MBZ in cancer types with the highest case representation in this series (prostate, brain, breast, colorectal, pancreatic) using standardized RECIST 1.1 outcome criteria.
  • Pharmacokinetic studies to characterize human FBZ bioavailability and tissue distribution at anti-neoplastic doses, as FBZ data are derived predominantly from veterinary models.
  • Biomarker studies to identify predictors of response, including tumor GLUT expression, p53 status, P-glycoprotein expression, and Wnt pathway activation.
  • Systematic collection of adverse event data in human cancer patients using standardized CTCAE (Common Terminology Criteria for Adverse Events) grading.
  • Establishment of a prospective observational registry to systematically capture outcomes in patients self-administering these agents, as proposed by health educators including Dr. John Campbell (>3 million YouTube subscribers).
  • Investigation of potential chemosensitization effects of IVM/FBZ in combination with standard regimens (RCHOP, FOLFOX, gemcitabine), given the multiple cases suggesting enhanced chemotherapy efficacy when used concurrently.

5. Limitations

This analysis carries fundamental methodological limitations that preclude causal inference:

  • Level of Evidence: The case series format represents a low level of evidence (Oxford CEBM Level 4). No control group, randomization, or blinding was applied.
  • Selection Bias: Reports were voluntarily submitted or shared publicly, creating substantial positive outcome bias.
  • Data Quality: The majority of cases rely on unverified self-reported outcomes. Independent radiographic, laboratory, or histological verification was not systematically obtainable.
  • Causality: Given the frequent co-administration of conventional therapies, causal attribution of any observed responses to FBZ/IVM/MBZ is not possible.
  • Outcome Measurement: Non-standardized outcome terminology was used across cases. RECIST criteria were not consistently applied.
  • Missing Data: Critical prognostic variables including performance status, comorbidities, prior treatment history, and biomarker status were inconsistently reported.
  • Source Reliability: A primary source (Dr. William Makis, X.com) represents a single physician whose posts have been subject to social media restriction and legal proceedings in Canada, introducing potential reliability concerns.
  • Publication Bias: Cases with adverse outcomes, lack of response, or deaths attributable to the regimen are systematically under-represented in the public domain.

6. Conclusions

This descriptive analysis of 767 patient-reported and physician-reported outcomes constitutes the largest known systematic compilation of FBZ, IVM, and MBZ use in human oncology. The breadth of cancer types represented — 31 subtypes — and the volume of cases in which favorable responses were reported, including in advanced-stage cancers with historically poor prognoses, warrant the generation of formal scientific hypotheses. Several cases include objective radiographic data and represent physician-documented, not merely patient-reported, outcomes.

However, the evidentiary foundation for clinical adoption of these agents in oncology remains insufficient. The methodological limitations inherent to case series analysis — selection bias, absence of controls, confounding by concurrent therapy, non-standardized outcome measurement — preclude firm conclusions regarding efficacy, safety, or therapeutic positioning.

Patients and caregivers facing advanced malignancy have a recognized right to explore and access information about novel therapeutic options. This compilation serves the legitimate function of centralizing that information and preserving real-world patient experiences. However, the ethical obligation of clinicians and researchers is to translate this observational signal into rigorous prospective investigation.

We call for adequately powered, prospective, controlled clinical trials of FBZ, IVM, and MBZ in priority cancer types, supported by international cooperative oncology groups. The potential for safe, affordable, globally accessible anti-cancer agents justifies urgent scientific attention. Until such evidence is available, these agents should not be adopted into routine oncologic practice outside of a clinical trial framework or carefully supervised compassionate use context.

7. Selected References

  1. Abughanimeh O et al. Fenbendazole as a Possible Therapeutic Agent Against Diffuse Large B-Cell Lymphoma. Annals of Hematology & Oncology. 2020.
  2. de Castro JG et al. Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia. J Oncol Pharm Pract. 2020;26(5):1288–1291. PMID 32611256.
  3. Lai Yuwen et al. A Review of Ivermectin Use in Cancer Treatment. Cancer Aesthetics Advisor. 2025.
  4. Dirksen EHC et al. Anticancer effects of fenbendazole in cancer cells in vitro and in vivo. Oncol Lett. 2022;23(5):166.
  5. Guerini AE et al. Mebendazole as a candidate for drug repurposing in oncology: an extensive review of current literature. Cancers (Basel). 2019;11(9):1284.
  6. Juarez M et al. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Am J Transl Res. 2013;5(3):285–293.
  7. Draganov D et al. Ivermectin and cancer treatment: repurposing antiparasitic drugs. Front Pharmacol. 2021.
  8. National Cancer Institute SEER Database. Cancer Stat Facts: Various Subtypes. Updated 2024.
  9. World Health Organization. Global Cancer Burden Growing amidst Mounting Need for Services. Press Release. February 2024.
  10. World Economic Forum. Global Cancer Funding Shortfall. 2024. https://www.weforum.org/stories/2024/03/global-cancer-funding-shortfall/
  11. Soares-Weiser K (Cochrane Review Editor-in-Chief). Editorial: Lack of evidence of effectiveness is not evidence of ineffectiveness. Cochrane Library. Accessed 2024.
  12. Fleming A. On the Antibacterial Action of Cultures of a Penicillium, with Special Reference to Their Use in the Isolation of B. influenzae. British Journal of Experimental Pathology. 1929. PMC2048009.
  13. Johnson PC et al. Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer. JAMA Oncology. 2025.
  14. OneDayMD Editorial Team. Fenbendazole, Ivermectin and Mebendazole for Cancer: Case Series of 767 Case Reports. The Medical Advisor, OneDayMD.com. May 2026. https://www.onedaymd.com/2024/02/fenbendazole-cancer-success-stories.html

Appendix A: Evidence Quality Assessment

Using the Oxford Centre for Evidence-Based Medicine (CEBM) 2011 Levels of Evidence framework:

Evidence Category CEBM Level Application to This Compilation
Peer-reviewed case reports (Abughanimeh 2020, de Castro 2020)Level 4Highest quality data within this corpus. Limited to individual cases or small series.
Physician-documented cases with imaging (Makis et al., 2023–2026)Level 4–5Physician-reported; imaging referenced but not independently verified by study authors.
Patient-reported testimonials (social media, forums)Level 5Anecdotal; subject to all limitations described in Section 5.
Preclinical mechanistic data (in vitro / animal)N/ASupports biological plausibility; cannot be extrapolated directly to human outcomes.

Overall Evidence Grade for Clinical Adoption: INSUFFICIENT. Hypothesis-generating only. Formal clinical trials required before any therapeutic recommendation can be issued.

Appendix B: Glossary of Key Terms

Term Definition
Fenbendazole (FBZ)Benzimidazole anti-parasitic agent (veterinary); C15H13N3O2S; inhibits tubulin polymerization and glucose uptake.
Ivermectin (IVM)Macrocyclic lactone; human-approved anti-parasitic; P-glycoprotein inhibitor, Wnt pathway suppressor.
Mebendazole (MBZ)Human-approved benzimidazole (WHO Essential Medicine); structural analog of FBZ.
Complete Remission (CR)Disappearance of all target lesions; no new lesions; normalization of tumor markers.
Partial Response (PR)≥30% decrease in sum of target lesion diameters per RECIST 1.1 criteria.
RECIST 1.1Response Evaluation Criteria in Solid Tumors version 1.1; standard framework for tumor response assessment in clinical trials.
Tumor NecrosisCell death within a tumor mass; on PET/CT manifests as photopenia (absence of metabolic activity) indicating cessation of viable tumor metabolism.
Warburg EffectPreferential utilization of glycolysis over oxidative phosphorylation by cancer cells, exploited as a therapeutic target by GLUT inhibitors.

— End of Manuscript —

This manuscript has not yet completed peer review and should not be cited as established clinical evidence.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: May 2026 Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Table of Contents: Editor's Preface Introduction Fenbendazole and Iverme...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

Fenbendazole and Ivermectin for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

By Editorial Team
Image
Summary Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited effective therapies and poor survival, especially in stage 4 disease. Repurposing antiparasitic agents such as fenbendazole and ivermectin has garnered interest due to their demonstrated anti-cancer properties in preclinical studies. Methods: We reviewed and synthesized 35 detailed case reports from 2022 to 2026 documenting the clinical use of fenbendazole and ivermectin, alone or in combination with standard therapies, in patients with advanced pancreatic cancer. Tumor markers, imaging outcomes, and clinical responses were analyzed alongside mechanistic literature. Results: Across cases, patients exhibited marked reductions in CA19-9 tumor markers (often >70%), significant tumor shrinkage on imaging, and improved clinical status. Responses were observed even in chemotherapy-resistant and metastatic disease. Mechanistic studies support multiple anti-cancer effects of...
Read more

Archive

Show more